Nearly six months into the coronavirus pandemic, the world waits nervously wondering if there is any end in sight. Roughly 19 million cases of COVID-19 have been confirmed globally with over 700,000 deaths. In the United States alone, 160,000 lives have been lost to the devastating disease and nearly 5 million coronavirus cases have been confirmed across the nation.
In the months since the pandemic began, some of the most prominent names in the pharmaceutical industry have stepped up to develop coronavirus vaccines, therapeutics, and treatments at an unparalleled scale. Major competitors have entered unprecedented vaccine partnerships in an effort to accelerate the development timeline and bring effective coronavirus solutions to market sooner and safer. At this moment, there are 199 potential COVID-19 vaccines in development at various phases of the clinical process.
If you're having a tough time keeping track of the companies working on a potential COVID-19 vaccine, you're not alone. These are the eight stocks you should train your focus on as the coronavirus vaccine race narrows.
5 Winning Stocks Under $49
We hear it over and over from investors, “I wish I had bought Amazon or Netflix when they were first recommended by the Motley Fool. I’d be sitting on a gold mine!” And it’s true. And while Amazon and Netflix have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $49 a share! Simply click here to learn how to get your copy of “5 Growth Stocks Under $49” for FREE for a limited time only.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.